Partnership to integrate Qure.ai’s smart artificial intelligent technology to detect lung cancer early on
India-Sweden healthcare Innovation Centre and its knowledge partner AstraZeneca India collaborated with the Directorate of Health Services (DHS) Jammu to integrate Qure.ai’s smart artificial intelligent technology to detect lung cancer early on.
Under the aegis of Indo Sweden Healthcare Innovation Centre (ISHIC), Qure.ai is scaling-up the integration of its AI-powered chest x-ray interpretation tool that can benefit early and easy detection of lung diseases including lung cancer.
Cecilia Oskarsson, Swedish Trade Commissioner to India said, “We are delighted to initiate this first project in Jammu towards early screening and diagnosis of lung diseases in the state. We look forward to supporting the start-up ecosystem and the states towards building an innovative ecosystem in the country.”
Dr Sanjeev Panchal, Country President and Managing Director, AstraZeneca India said, “We celebrate the progress that has been made in cancer care, including advances in screening, the development of innovative therapies, greater public-private collaboration and increased prioritisation of health equity. As a global cancer community, we have many reasons to be optimistic about the future. We are moving ever closer to achieving our ambition eliminating cancer as a cause of death.”
Prashant Warier, CEO, Qure.ai said, “AstraZeneca has helped us spread our offering across the world that has led to approximately 170,000 scans in 25 countries, with high malignancy risk lung nodules identified in 1.6 per cent of scans. Today we are tapping further into technology to enable faster diagnosis and speedy treatments.”
The AI powered chest X-ray is designed to distinguish lung nodules in under a minute and minimise the chances of lung cancers going undetected. Importantly, this tool is being accessed in primary care setting where x-rays are utilised most commonly.
- Advertisement -